ArticleCureus2025
Bilateral Retinal Vasculitis in Systemic Lupus Erythematosus: A Case Series of Three Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a long-term autoimmune disorder that affects multiple organ systems and presents with a broad spectrum of symptoms, ranging from mild, nonspecific complaints to severe, potentially life-threatening complications. It is commonly seen in females but may occur in males. Ocular involvement is common in SLE patients. These ophthalmic symptoms can develop during the course of the disease or may be the initial sign. Although rare, sudden vision loss due to retinal vessel involvement can be the first presentation of SLE. This case series highlights a rare manifestation of SLE bilateral retinal vasculitis as either the initial or subsequent presentation of the disease. The mean age with standard deviation of the patients in this series was 29.67±9.44 years. Of the three patients, one was male and two were female. In one case, retinal vasculitis was the initial manifestation of SLE, while in the other two, it developed during the disease. All patients were treated with intravenous methylprednisolone (MP), followed by oral prednisolone at a dose of 1 mg/kg of body weight, in combination with monthly cyclophosphamide. Partial clinical improvement was observed in all cases. Retinal vasculitis, whether isolated or accompanied by involvement of other organs, should be considered in the differential diagnosis of visual disturbances in SLE patients. Early recognition and prompt treatment are critical to prevent irreversible retinal damage and complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.